SCM
CTMX icon

Sterling Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Sterling Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-37,751
Closed -$863K – 868
2018
Q2 		$863K Sell
37,751
-45
-0.1% -$1.15K 0.01% 664
2018
Q1 		$1.07M Hold
37,796
– – 0.01% 587
2017
Q4 		$798K Buy
+37,796
New +$784K 0.01% 697

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Sterling Capital Management's CTMX Position: Q3 2018 in Review

Sterling Capital Management sold out of CytomX Therapeutics (CTMX) in Q3 2018, closing a stake of 37,751 shares — an estimated $863K sold.

Sterling Capital Management first reported a position in CTMX in Q4 2017 and held it in 3 quarters. The position peaked at $1.07M in Q1 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q3 2018.

  • Sterling Capital Management reported no remaining CytomX Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Sterling Capital Management sold 37,751 CytomX Therapeutics shares in Q3 2018, an estimated $863K.
  • Sterling Capital Management first reported a position in CytomX Therapeutics in Q4 2017 and held it in 3 quarters.
  • Sterling Capital Management's CytomX Therapeutics position peaked at $1.07M in Q1 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2018.

Based on Sterling Capital Management's 13F filing for Q3 2018, filed 1 Nov 2018.